reports
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for...
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 – Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA submission – LOS ANGELES, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has gran...
- Jonathan Moreland
WHF WHITEHORSE FINANCE INC.
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
CUBE CUBESMART
CE CELANESE CORPORATION
AZO AUTOZONE INC.
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
NB NIOCORP DEVELOPMENTS LTD
OXM OXFORD INDUSTRIES INC.
AP AMPCO-PITTSBURGH
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
ELAN ELANCO ANIMAL HEALTH INC.
AMCR AMCOR PLC
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
DHC INC.
COO DIVERSIFIED HEALTHCARE TRUST
RZLT THE COOPER COMPANIES INC.
AZYO REZOLUTE
IMNM INC.
ACVA AZIYO BIOLOGICS
BMEA IMMUNOME
PBBK ACV AUCTIONS INC.
OWL BIOMEA FUSION
IMMX INC.
NUVL PB BANKSHARES
MAIA INC.
LIN BLUE OWL CAPITAL INC
WEST IMMIX BIOPHARMA INC
SMRT NUVALENT INC
FISV MAIA BIOTECHNOLOGY INC
XELB LINDE PUBLIC LIMITED COMPANY
SI WESTROCK COFFEE COMPANY LLC
ASST SMARTRENT INC
GMRE FISERV
SEVN INC.
MPTI XCEL BRANDS INC.
SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
M-TRON INDUSTRIES
INC.
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
NRIM NORTHRIM BANCORP INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
ALTG ALTA EQUIPMENT GROUP INC.
AMR ALPHA METALLURGICAL RESOURCES INC
NEXT NEXT CAPITAL
NRDY NERDY INC.
IMMX IMMIX BIOPHARMA INC
QDEL QUIDEL CORP
SMRT SMARTRENT INC
MNR MACH NATURAL RESOURCES LP
GAM GENERAL DE ALQUILER DE MAQUINARIA
TENX TENAX THERAPEUTICS INC.
AFCG AFC GAMMA
INC.
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten...
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants – Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lie...
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten...
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.0...
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase ...
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis – NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% – – NEXICART-2 final readout and BLA submission planned in 2026 – LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWS...
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Lau...
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix’s U.S. launch and commercial buildout for NXC-201 in relapsed/refractory AL Amyloidosis, a serious, rare, blood disease with no currently approved FDA therapies - LOS ANGELES, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”)...
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected f...
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlan...
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Inn...
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA. Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time. The Company will be available for o...
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Me...
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-u...
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare...
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY. The Company will be available for one-on-one meetings du...
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its on...
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 – On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 50% enrollment milestone has already been surpassed in ...
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Boa...
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors – Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with her inve...
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference being held on November 11-13, 2025 at the Lotte New York Palace Hotel in New York, NY. The Company will be available for one-on-one meetings during the conference. Inter...
Immix Biopharma Announces Other Serious Diseases Strategy
Immix Biopharma Announces Other Serious Diseases Strategy – Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced imp...
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Poten...
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion – Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious disea...
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progre...
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis – National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ann...
Immix Biopharma Attends FDA CEO Forum in Washington DC
Immix Biopharma Attends FDA CEO Forum in Washington DC – Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters in Silver Spring, MD, on June 5, 2025....
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Int...
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. – NXC-201 met primary endpoint with a complete response (CR) rate of 70% (7/10 patients) – – No relapses recorded to-date; no safety signals identified – – Immix plans Biologics License Application (BLA) for FDA approval – – Results were presented by Heather ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.